Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tulisokibart in moderately to severely active Crohn's disease
NL-OMON59775Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing tulisokibart with placebo (2 arms). Primary endpoints: Percentage of participants achieving clinical remission per Crohn's Disease Activity Index score at Week 52, Percentage of participants achieving clinical remission per stool frequency and abdominal pain score at Week 52 and 4 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59775.